Conning Inc. Has $667,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Conning Inc. increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 635 shares of the biopharmaceutical company’s stock after buying an additional 16 shares during the period. Conning Inc.’s holdings in Regeneron Pharmaceuticals were worth $667,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Norges Bank acquired a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $932,571,000. Global Assets Advisory LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth $339,594,000. Capital International Investors boosted its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. First Trust Advisors LP raised its holdings in shares of Regeneron Pharmaceuticals by 115.2% during the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after buying an additional 195,902 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after buying an additional 184,561 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CEO Leonard S. Schleifer sold 9,064 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the sale, the chief executive officer now directly owns 55,134 shares of the company’s stock, valued at $55,984,717.62. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, CEO Leonard S. Schleifer sold 9,064 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total value of $9,203,857.52. Following the sale, the chief executive officer now directly owns 55,134 shares of the company’s stock, valued at $55,984,717.62. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at $1,397,202. The disclosure for this sale can be found here. Insiders have sold a total of 16,559 shares of company stock valued at $17,087,606 over the last three months. 7.48% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Royal Bank of Canada increased their target price on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upped their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Argus raised their price objective on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. TD Cowen boosted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 27th. One analyst has rated the stock with a sell rating, three have given a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,108.45.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $2.47 during trading on Wednesday, hitting $1,199.29. 308,084 shares of the company traded hands, compared to its average volume of 467,276. The firm has a market cap of $132.14 billion, a P/E ratio of 35.19, a price-to-earnings-growth ratio of 3.12 and a beta of 0.13. The stock’s fifty day moving average is $1,091.14 and its 200 day moving average is $1,006.29. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $769.19 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.79 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.